Aeglea BioTherapeutics, Inc. (AGLE) News

Aeglea BioTherapeutics, Inc. (AGLE): $12.01

0.97 (+8.79%)

POWR Rating

Component Grades

Momentum

D

Stability

F

Sentiment

Quality

D

Add AGLE to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#246 of 339

in industry

Filter AGLE News Items

AGLE News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

AGLE News Highlights

  • AGLE's 30 day story count now stands at 3.
  • Over the past 22 days, the trend for AGLE's stories per day has been choppy and unclear. It has oscillated between 1 and 1.

Latest AGLE News From Around the Web

Below are the latest news stories about AEGLEA BIOTHERAPEUTICS INC that investors may wish to consider to help them evaluate AGLE as an investment opportunity.

Aeglea BioTherapeutics Announces Grants of Inducement Awards

Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that Aeglea's independent Compensation Committee of the Board of Directors approved the grants of stock options to purchase an aggregate of 351,750 shares of common stock and a grant of 18,912 restricted stock units to four non-executive employees as equity inducement awar

Yahoo | November 22, 2023

Aeglea BioTherapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

Aeglea BioTherapeutics, Inc. ("Aeglea" or the "Company") (NASDAQ:AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced its third quarter 2023 financial results and provided program and corporate updates.

Yahoo | November 9, 2023

Aeglea BioTherapeutics to Participate in Upcoming November Investor Conferences

Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that management will participate in the following investor conferences:

Yahoo | October 31, 2023

Aeglea BioTherapeutics to Participate in Upcoming September Conference

Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that management will participate in the Stifel 2023 Immunology & Inflammation Virtual Summit.

Yahoo | September 14, 2023

Aeglea BioTherapeutics Announces Reverse Stock Split

Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced it will effect a reverse stock split of all outstanding shares of Aeglea's common stock at a ratio of 1-for-25. Aeglea expects its common stock to begin trading on a split-adjusted basis on the Nasdaq Capital Market as of the commencement of trading on September 8, 2023.

Yahoo | September 7, 2023

Aeglea BioTherapeutics Expands Executive Leadership Team with Appointment of Industry Veterans Scott Burrows and Heidy Abreu King-Jones

Aeglea BioTherapeutics, Inc. ("Aeglea") (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced the appointment of Scott Burrows, as Chief Financial Officer and Heidy Abreu King-Jones as Chief Legal Officer and Corporate Secretary. Both will report to Cameron Turtle, Chief Operating Officer of Aeglea, and join the Company's leadership team. Aeglea also announced that

Yahoo | September 5, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We're starting off the week with a breakdown of the biggest pre-market stock movers worth reading about on Monday morning!

William White on InvestorPlace | August 28, 2023

Aeglea BioTherapeutics Reports Second Quarter 2023 Financial Results

Aeglea BioTherapeutics, Inc. ("Aeglea" or the "Company") (NASDAQ:AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced second quarter 2023 financial results and provided program and corporate updates.

Yahoo | August 11, 2023

Aeglea BioTherapeutics Announces Sale of Pegzilarginase to Immedica Pharma

Aeglea BioTherapeutics, Inc. ("Aeglea") (NASDAQ:AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with best-in-class potential to transform the treatment of inflammatory bowel disease ("IBD"), today announced that it has entered into an agreement to sell the global rights to pegzilarginase, an investigational treatment for the rare metabolic disease Arginase 1 Deficiency ("ARG1-D"), to Immedica Pharma AB ("Immedica") for $15 million in upfront cash proceeds and up to $

Yahoo | July 27, 2023

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's time for a final dive into the biggest pre-market stock movers this week as we check out what's happening on Friday!

William White on InvestorPlace | June 23, 2023


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!